Convergent epigenetic evolution drives relapse in acute myeloid leukemia
eLife · 22.04.2024 · 13
DOI: 10.7554/elife.93019 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 22.04.2024. Verfasst von Kevin Nuno und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Graduate Program, Stanford University School of Medicine, Stanford, United States. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Epigenesis, Genetic. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology Graduate Program, Stanford University School of Medicine, Stanford, United States.
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, United States.
- Cancer Institute, Stanford University School of Medicine, Stanford, United States.
- Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, United States.
- University of California Irvine School of Medicine, Irvine, United States.
- Department of Pathology, Stanford University, Stanford, United States.
ORCID-Profile: Kevin Nuno, Armon Azizi, Caleb Lareau, Ravindra Majeti
Förderung
- NHGRI NIH HHS
- NIH HHS
- NCI NIH HHS
- American Society of Hematology
- Leukemia and Lymphoma Society
- National Institutes of Health
Zitieren
APA
Nuno, K., Azizi, A., Koehnke, T., Lareau, C., Ediriwickrema, A., Corces, M. R., Satpathy, A. T., & Majeti, R. (2024). Convergent epigenetic evolution drives relapse in acute myeloid leukemia. eLife, 13. https://doi.org/10.7554/elife.93019
Vancouver
Nuno K, Azizi A, Koehnke T, Lareau C, Ediriwickrema A, Corces MR, et al. Convergent epigenetic evolution drives relapse in acute myeloid leukemia. eLife. 2024;13. doi:10.7554/elife.93019
BibTeX
@article{Nuno2024,
author = {Nuno, Kevin and Azizi, Armon and Koehnke, Thomas and Lareau, Caleb and Ediriwickrema, Asiri and Corces, M Ryan and Satpathy, Ansuman T and Majeti, Ravindra},
title = {Convergent epigenetic evolution drives relapse in acute myeloid leukemia},
journal = {eLife},
year = {2024},
volume = {13},
doi = {10.7554/elife.93019}
}
EUVIMED